Raymond James is the latest to get on the Vermilion bandwagon, after our cover story last week and contributor Fabrice Taylor recommending the stock on BNN Bloomberg, setting an "outperform" rating and a target of $52 (Canadian).

PI Financial begins coverage of this stock, which we featured in the Digest in May, with a "buy" and a target of $2.25.

RBC reduces its price target to $22 from $25, giving the stock 22% upside, and maintains "outperform" after the CEO stepped down, the company reduced its forecast and announced a strategic review. Desjardins downgrades to "buy" and cuts the target to $29 from $32.

CIBC is reducing its EPS estimates and price target projections on a number of paper and forestry companies including CFF, which sees its target cut to $5.50 from $9.

RBC maintains its "outperform" rating and price target of $300 (U.S.), which indicates a gain of 41%, after conducting its quarterly distributor survey of the beer industry saying investors should: "...buy on recent weakness"...and that... "the Canopy Growth investment was the result of a forward looking management team and board of directors, and not deteriorating beer trends."

RBC raises the price target to $38 from $30, implying 20% gains, and maintains "outperform".

RBC says these three biotechs could double in the next six-to12 months based on:

"...underappreciated pipelines, relatively near-term catalysts, and a valuation disconnect we think could enable substantial upside opportunity on favourable developments."

Credit Suisse lifts the target to a very specific $8.44 from $7.19 citing the possibility of the company exceeding its 2020 financial targets.

B. Riley FBR hikes the target to $84 from $76.

Tilray (NASDAQ:TLRY) has surged another 50% as I write this after its CEO told CNBC cannabis is a "great hedge" for alcohol, tobacco and pharmaceutical companies. That's it. That's all he said. And yet it's apparently enough to send this company with something like just under $30 million in revenue to a market cap of about $14.4 billion.

I talked to a very smart hedge fund manager recently with a great track record who said cannabis is a bubble but that bubbles are tricky because you want to ride the bubble or else you leave a ton of money on the table. But you also have to hedge those long bets with some short positions because when the mania ends, and I'm paraphrasing here, it will be ugly.

Tilray is tough to short though because the float is relatively small at 93 million shares and most of them are held by retail investors. The percentage of Tilray shares being shorted is about 34%, according to analytics firm S3 Partners. Point being: be careful out there.

Kirkland Lake Gold (TSX:KL) is buying 14.7 million common shares of Osisko Mining (TSX:OSK) through a private placement at $1.70 per share or about $25 million. Kirkland Lake now owns 13.6% of Osisko, up from 8.6%.

Eldorado Gold (TSX:ELD) is seeking 750 million euros in damages from Greece it says were incurred caused by delays in getting permits for its Skouries project. Greece's government says the company submitted a deficient plan to build a metallurgical plant.

Sunniva (CSE:SNN) has struck a $10 million bought deal financing through a syndicate of underwriters led by Beacon Securities and Canaccord Genuity, which is buying 1.9 million units at $5.27 per unit.

Alibaba (NYSE:BABA) will set up an artificial intelligence semiconductor subsidiary, and is teaming with SAP to ofer the company's products on its cloud infrastructure.